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Abstract.
BACKGROUND: Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women.
Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined.
OBJECTIVE: To evaluate the effects of early treatment with Denosumab (6 12 months after starting AIs) compared to a delayed
treatment in BC women.
METHODS: In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with
AIs therapy; they were divided as: study group (starting Denosumab 6 12 months after AIs) and control group (> 12 months). At
the baseline (T0) and at 18 months (T1), we evaluated the lumbar spine (LS) Tscore and femoral neck (FN) Tscore. Furthermore,
at T1 we assessed the incident fragility fractures.
RESULTS: Fifty-nine BC survivors (mean age: 61.5 ± 11.5 years) were included: 28 with Early Denosumab and 31 with Late
Denosumab. At T1, the study group did not show any incident hip or vertebral fragility fracture, whereas the Late Denosumab
group showed 2 incident hip fractures (6.5%) and 4 (12.9%) vertebral fragility fractures. Early Denosumab showed a significant
positive effect on both LS (p = 0.044) and FN (p = 0.024) Tscore variations.
CONCLUSION: Taken together, our findings suggest that an early start of Denosumab might be considered for the osteoporosis
management in BC women undergoing AIs.
Keywords: Osteoporosis, risk of fractures, breast cancer, denosumab, bone health
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1. Introduction 1
Breast cancer (BC) is the most frequently diagnosed 2
cancer in women, accounting for 30% of female can- 3
cers, and the first cause of cancer death in women, fol- 4
lowed by colorectum cancer [1,2]. The disease course 5
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has been changed in recent years with a great im-6
provement of the 5-years survival estimated about 90%7
worldwide [2], and 87% in Italy [3].8
BC management might consist of several thera-9
peutic strategies, including surgery (mastectomy and10
quadrantectomy), often followed by local radiother-11
apy and chemotherapy, guided by tumor histology sub-12
type. These interventions might lead to several dis-13
abling complications, including breast cancer-related14
lymphedema, BC-related fatigue, shoulder dysfunction,15
postural imbalance, axillary web syndrome, physiolog-16
ical disorders [4–6].17
Breast surgery might lead to a significant physical18
and psychological impact in post-menopausal women,19
suffering range of motion limitation, pain and dis-20
comfort, a patient-tailored rehabilitation intervention is21
mandatory to prevent or resolve these complications. In22
the literature, several studies have shown that, regard-23
less of surgery received, a low-intensity rehabilitation24
program is effective in recovering upper limb mobility25
and reducing disability and pain [7,8].26
Adjuvant hormonal treatment is indicated in all pa-27
tients with breast cancer with hormone receptor pos-28
itive (ER+) after surgery to prevent disease recur-29
rence [9,10]. Hormone Replacement Therapy (HRT)30
can be individualized based on the clinical evalua-31
tion, as various drugs can be administrated, such as32
estrogen receptor modulators (SERMs), aromatase in-33
hibitors (AIs) and luteinizing hormone-releasing hor-34
mone (LHRH) agonists [9]. Among the SERMs, the35
most used in common practice is tamoxifen, in associa-36
tion or not with LHRH analogues, which is indicated37
in the treatment of pre-menopausal women with hor-38
mone receptor positive breast cancer [11]. On the other39
hand, AIs are utilized in post-menopausal women with40
ER+ [12].41
In this scenario, AIs are considered as powerful42
inhibitors of estrogen production, acting by binding43
reversibly (non-steroidal inhibitors), or irreversibly44
(steroidal inhibitors) and deactivating the aromatase en-45
zyme, responsible for the conversion of androgens into46
estrogens [13]. However, these therapies could have a47
detrimental impact on bone health in BC women, pro-48
moting bone resorption [14,15]. Indeed, the low circu-49
lating estrogen levels could lead to a high differentiation50
of the pre-osteoclasts, an increase in the survival of os-51
teoclasts and an increased apoptosis of osteoblasts [14].52
As a result, the osteoclasts activity will be greater than53
the activity of osteoblasts, with a negative effect on bone54
remodeling, leading to a cancer treatment-induced bone55
loss (CTIBL), during AIs administration or after the56
end of treatment [14–16]. Therefore, AIs assumption 57
represents a noteworthy risk factor for the development 58
of osteoporosis in BC survivors, as their prolonged use 59
inevitably leads to a reduction in bone mineral density 60
(BMD) [17] and an increased risk of fragility hip and 61
vertebral fractures [18]. 62
In this context, CTIBL is considered an emerging is- 63
sue in BC survivors [19], and the Italian National Reg- 64
ulatory Agency for Drugs included BC women aged 65
> 50 years treated with AIs in the subjects respecting 66
the reimbursement criteria for anti-osteoporotic phar- 67
macological treatments [20], thus recommending bis- 68
phosphonates (alendronate, risedronate, zoledronate) or 69
Denosumab as a first-line approach [20]. 70
Denosumab is a fully human IgG2 monoclonal anti- 71
body that binds and inhibit the receptor activator of nu- 72
clear factor kappa-B ligand (RANKL), a key mediator 73
for bone resorption, with high affinity and high speci- 74
ficity. RANKL signaling cascade normally intervenes 75
in promoting the survival of osteoclasts [21]. Deno- 76
sumab assumption reduces bone resorption at both cor- 77
tical and trabecular level [14]. Moreover, it has been 78
shown that Denosumab 60 mg subcutaneously admin- 79
istered every 6 months in combination with vitamin 80
D supplementation might reduce the risk of fragility 81
fractures in BC survivors [14]. In addition to its an- 82
tiresorptive effect, Denosumab also plays a role in im- 83
proving BC survival, mainly by reducing the develop- 84
ment of bone metastases [22], and reducing back pain- 85
related disability [23,24]. Furthermore, patients under- 86
going Denosumab showed high persistence and adher- 87
ence that might lead to a high therapeutic effect on bone 88
health, reducing the risk of fragility fractures [25]. 89
Although the effectiveness of Denosumab in reduc- 90
ing bone loss in BC women undergoing AIs is well 91
recognized [11,13,15,18,22], the appropriate time for 92
intervention is yet to be clearly defined. Some stud- 93
ies [14,15,18] showed the effectiveness of Denosumab 94
in preventing fragility fractures and BMD loss at the 95
start of HRT therapy; these findings have been con- 96
firmed by a recent metanalysis [26] in post-menopausal 97
women undergoing AIs. On the other hand, evidence 98
also showed that the effectiveness of Denosumab on 99
BMD might still be preserved even if started after adju- 100
vant therapy [15,27,28]. Therefore, in the present study, 101
we sought to evaluate the effects of an early treatment 102
with Denosumab (6 12 months after starting AIs) com- 103
pared to a delayed treatment in BC post-menopausal 104
women. 105
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2. Materials and methods106
2.1. Participants107
In this retrospective case-control study, we included108
medical records of BC survivors referring to the Osteo-109
porosis Outpatient Service, “Paolo Giaccone Univer-110
sity Hospital”, Palermo, Italy over a 24-month period,111
from January 2017 to January 2019. Inclusion crite-112
ria were: 1) post-menopausal women aged > 50 years;113
2) diagnosis of histologically confirmed non-metastatic114
BC; 3) AIs therapy; 4) absence of prevalent osteo-115
porotic fractures; 5) use of Denosumab 60 mg subcuta-116
neously each 6 months as anti-osteoporosis treatment.117
We excluded: 1) women that previously assumed anti-118
osteoporosis drugs; 2) women in treatment with others119
anti-neoplastic therapy; 3) women with metastases.120
The study was approved by the Ethics Committee of121
the “Paolo Giaccone University Hospital” in Palermo,122
Italy (approval number: 06/2019). Researchers provided123
to protect the privacy and the study procedures accord-124
ing to the Declaration of Helsinki, with pertinent Na-125
tional and International regulatory requirements.126
2.2. Intervention127
All study participants underwent Denosumab 60 mg128
by subcutaneous injection every 6 months, combined129
with an oral supplementation of cholecalciferol 25,000130
IU (once every 15 days) and calcium citrate 500 mg131
(once per day).132
The study cohort was divided according to the timing133
of the start of Denosumab treatment: study group, start-134
ing Denosumab no more than 12 months after the first135
AIs administration, and control group, starting Deno-136
sumab more than 12 months after the first AIs adminis-137
tration.138
2.3. Outcome measures139
At the baseline (T0) and at the 18-month follow-140
up evaluation (T1), we collected the following data:141
lumbar spine (LS) bone mineral density (BMD), LS142
Tscore, LS Zscore, femoral neck (FN) BMD, FN143
Tscore, FN Zscore, serum levels of 25-hydroxyvitamin144
D [25(OH)vit.D], calcium, parathyroid hormone (PTH),145
and alkaline phosphatase (ALP). Furthermore, at T1146
we assessed the number of incident hip and vertebral147
fragility fractures.148
2.4. Statistical analysis149
The statistical analysis was performed using R soft-150
ware (R Foundation for Statistical Computing, Vienna, 151
Austria). Continuous variables were expressed as means 152
and standard deviations, whereas the categorical vari- 153
ables were expressed as absolute numbers and percent- 154
ages. For the statistical modeling we used the classi- 155
cal linear regression model to evaluate the effect net 156
of any confounding variables. P -values < 0.05 were 157
considered statistically significant. 158
3. Results 159
Of the 255 subjects recruited, 196 did not match the 160
eligibility criteria and were excluded. Thus, 59 BC post- 161
menopausal women (mean age: 61.5 ± 11.5 years) were 162
included in the final analysis. The study cohort was di- 163
vided into two groups based on the start of Denosumab 164
treatment: the study group (Early Denosumab) included 165
28 patients, while the control group (Late Denosumab) 166
included 31 patients. No statistically significant differ- 167
ences were found between the two groups at baseline 168
for the collected outcomes, as shown in Table 1. 169
At T1, the study group did not show any incident hip 170
or vertebral fragility fracture. On the other hand, it was 171
interesting to notice that the Late Denosumab group 172
showed 2 (6.5%) incident hip fractures and 4 (12.9%) 173
incident vertebral fragility fractures. At T1, the study 174
group showed higher BMD values compared to control, 175
both for LS (0.79 ± 0.1 g/cm3 vs 0.74 ± 0.2 gr/cm3) 176
and FN (0.88 ± 0.1 g/cm3 vs 0.80 ± 0.3 g/cm3), 177
and consequently higher T-scores (LS −1.75 ± 1.3 vs 178
−1.97 ± 1.1 and FN −1.25 ± 1.7 vs −1.51 ± 1.1). 179
We also performed a linear regression model consid- 180
ering the T-score at T0 to assess any difference between 181
groups depending on the baseline status of the patient. 182
Table 2 shows the estimates of the regression coeffi- 183
cients of the model for the variation of the LS T-score 184
and the FN T-score. Considering the results of the main 185
effects, an early administration of Denosumab 60 mg 186
within one year from AIs therapy initiation showed a 187
statistically significant positive effect on the variation 188
of the T-score in both LS Tscore (+0.169; p = 0.044) 189
and FN Tscore (+0.234; p = 0.024) 190
4. Discussion 191
AIs are considered to be the most administered hor- 192
monal therapies in post-menopausal women with BC. 193
However, their assumption is detrimental for bone 194
health in these patients, as they might cause reduction 195
Galley Proof 4/06/2021; 9:54 File: bmr–1-bmr210012.tex; BOKCTP/xjm p. 4
4 D. Scaturro et al. / Early Denosumab for the prevention of osteoporotic fractures in BC women undergoing AIs
Table 1
Baseline characteristics of the study population
Total (n = 59) Study group (n = 28) Control group (n = 31) P value
Age (years) 61.5 ± 11.5 62.6 ± 11.9 60.4 ± 11.2 0.486
BMI (kg/m2) 26.4/6.3 26.4/6 26.5/6.7 0.987
Laterality (right/left/bilateral) 26/27/6 12/13/3 14/14/3 0.958
Type of breast cancer (lobular/ductal) 16/43 8/20 8/23 0.877
Histological type (in situ/infiltrative) 3/56 2/26 1/30 0.441
Previous femur fragility fractures 1 (1.69%) 1 (3.57%) 0 (0%) 0.972
Previous vertebral fragility fractures 47 (79.66%) 20 (71.4%) 27 (87.1%) 0.142
LS BMD (g/cm2) 0.8 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.754
LS Tscore −2.1 ± 1.2 −2.1 ± 1.2 −2.2 ± 1.3 0.732
LS Zscore −0.6 ± 1.2 −0.6 ± 1.3 −0.7 ± 1.1 0.745
FN BMD (g/cm2) 0.7 ± 0.3 0.7 ± 0.4 0.8 ± 0.2 0.591
FN Tscore −1.5 ± 1.1 −1.4 ± 1 −1.5 ± 1.2 0.665
FN Zscore −0.5 ± 1.3 −0.5 ± 1.4 −0.5 ± 1.1 0.963
Serum 25(OH)vit. D (ng/ml) 30.1 ± 15.8 27 ± 13.2 32.9 ± 17.6 0.153
Serum calcium (mg/dl) 9.1 ± 1.4 9 ± 1.5 9.2 ± 1.2 0.517
Serum PTH (pg/ml) 52.4 ± 23.6 52.6 ± 25.3 52.3 ± 22.4 0.965
Serum ALP (ug/l) 12.5 ± 11.1 10.8 ± 7.4 14 ± 13.7 0.270
Continuous variables are expressed as means ± standard deviations; categorical variables are expressed as counts (percentages);
ratios are expressed as x/y. Abbreviations: BMI = body mass index; LS = lumbar spine; BMD = bone mineral density; FN =
femoral neck; 25(OH)vit. D = 25-hydroxy-vitamin D; PTH = parathyroid hormone; ALP = alkaline phosphatase.
Table 2
Regression model for the variation of lumbar and femoral T-score from baseline (T0) to the
18-month follow-up evaluation (T1)
Coefficients Estimate Std. error P value
Lumbar spine T-score at T1
Lumbar spine T-score in T0 −0.202 0.062 0.002
Early Denosumab 0.485 0.212 0.027
Age −0.004 0.005 0.372
Lumbar T-score in T0*Early Denosumab 0.169 0.086 0.024
Femoral neck T-score at T1
Femoral T-score in T0 −0.209 0.086 0.018
Early Denosumab 0.526 0.245 0.036
Age −0.006 0.007 0.328
Femoral neck T-score in T0*Early Denosumab 0.234 0.132 0.044
of BMD, with consequently hip and vertebral fragility196
fractures [17,18].197
In the present retrospective case-control study, we198
assessed the effects of Denosumab 60 mg sc. every199
6 months in women with non-metastatic BC on AIs200
therapy started no more than 12 months after the first201
AIs administration compared with the same therapy ini-202
tiated more than 12 months after the first AIs adminis-203
tration. We showed that an early treatment with Deno-204
sumab might have a preventive effect on incident verte-205
bral and hip fragility fractures, and a greater improve-206
ment in FN and LS T-scores compared to a delayed207
treatment. We also documented greater improvements208
in patients with previously deteriorated bone.209
In the literature, several studies have shown the ef-210
fectiveness of Denosumab in preventing negative ef-211
fects on bone mineral metabolism in patients affected212
by BC under AIs treatment. Firstly, Ellis et al. [15]213
analyzed the efficacy of Denosumab versus a placebo 214
in preventing bone health in women treated with AIs. 215
The results of the study confirmed the efficacy of Deno- 216
sumab compared to placebo in increasing BMD levels 217
in the trabecular and cortical bone; however, the time 218
of administration was not evaluated, as they only strati- 219
fied patients by duration of AIs therapy (six months or 220
more) stating no significant differences [15]. 221
The phase III Adjuvant Denosumab in postmeno- 222
pausal patients with hormone receptor-positive Breast 223
Cancer (ABCSG-18) trial showed that Denosumab 224
treatment resulted in increased lumbar and femoral neck 225
BMD compared to placebo, as well as delaying onset 226
of clinical fragility fracture [18]. However, the authors 227
reported that 16% of the patients were enrolled at start 228
of AIs therapy, whereas 84% of the patients were al- 229
ready under treatment; no clear assessment between the 230
adequate time to initiate Denosumab was stated. 231
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A recent meta-analysis [26] compared Denosumab232
versus zoledronic acid to prevent AI-associated frac-233
tures in postmenopausal early BC, showing that Deno-234
sumab started within 12 months from AIs might reduce235
the risk of fracture significantly compared with delayed236
treatment. However, the latter was performed only on237
two studies versus placebo and considering a subset of238
patients that crossed over due to deterioration of bone.239
Moreover, immediate vs late administration was com-240
parable at the 18 month cut-off, while the risk of frac-241
ture was reduced only at 36 months. On the other hand,242
Nakatsukasa et al. [28] evaluated the efficacy of Deno-243
sumab in the treatment of AIs-associated bone loss in244
a Japanese population, assessing a similar increase in245
LS BMD in patients who received AI and Denosumab246
simultaneously and in patients who had received AI247
before the initiation of the Denosumab therapy, with no248
significant difference.249
In the present study we found that BC women un-250
dergoing AIs starting the treatment with Denosumab251
within 12 months from AIs therapy might beneficiate252
in terms of fragility fracture prevention at 18 months253
follow-up compared to the same therapy performed254
after 12 months. Moreover, the early treatment with255
Denosumab seems to lead to a further increase of LS256
and FN T-scores compared to delayed treatment, and257
these effects might be greater in patients with reduced258
BMD. Indeed, it is crucial to define the better timing for259
starting antiresorptive agents to prevent fragility frac-260
tures in BC women undergoing AIs therapy. This study261
might be a step towards the better clinical management262
of these fragile patients.263
As bone metabolism is still a growing field of knowl-264
edge, several mechanisms might contribute to CTIBL,265
such as inflammation, hematological alterations, and266
different hormonal disbalance [29,30].267
However, it should be stressed that aside from phar-268
macological treatments, an adequate physical activity269
might play an important role in the prevention of bone270
loss in BC patients [31].271
We are aware that the present study is not free from272
limitations: first, the monocentric study design might273
not guarantee a high external validity; second, the sam-274
ple size was small due to the strict eligibility criteria;275
third, the study lacked a long-term follow-up evalua-276
tion, which could provide more information on the ad-277
herence and compliance to Denosumab therapy by the278
study participants.279
5. Conclusion 280
Taken together, these findings suggest that an early 281
starting of Denosumab treatment might be consid- 282
ered for the management of osteoporosis in BC post- 283
menopausal women undergoing AIs. The present study 284
could be considered as a starting point in this complex 285
scenario and further studies are warranted to provide 286
BC patients undergoing AIs with adequate indications 287
to prevent CTIBL and its detrimental complications. 288
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